azacitidine with checkpoint inhibitors for aml and mds
Published 6 years ago • 1.8K plays • Length 2:38Download video MP4
Download video MP3
Similar videos
-
2:37
immune checkpoint inhibitors for aml: mechanism, rationale & using azacitidine to boost response
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
3:34
anti-cd47 antibodies & azacitidine for aml and mds
-
4:55
checkpoint inhibitor combination approaches for aml/mds: an update
-
2:41
immunotherapy in aml: azacitidine plus checkpoint inhibitors
-
3:31
update on checkpoint inhibitor therapy for aml: salvage, frontline & azacitidine combination
-
5:42
immune checkpoint inhibitors in mds and aml
-
0:52
azacitidine in the treatment of mds
-
7:01
venetoclax azacitidine in frontline aml management
-
4:58
building blocks of hope - treatment of higher risk mds
-
3:49
cd47 discovery: flipping the script on cancer | stanford cancer institute
-
2:20
pevonedistat, azacitidine and venetoclax triplet therapy for aml, mds and cmml
-
1:40
azacitidine/hdac inhibitor combination for high risk aml: a promising pilot study
-
4:44
azacitidine quizartinib for patients with mds and mpns with flt3 or cbl mutation
-
5:36
venetoclax and azacitidine in mds patients
-
4:44
establishing the clinical benchmark of azacitidine in patients with mds
-
5:22
magrolimab azacitidine in mds and aml
-
2:47
combination therapies with azacitidine for mds
-
7:32
current immune checkpoint inhibitor trials in aml/mds
-
1:37
a phase i/ii trial of seclidemstat in combination with azacitidine for patients with mds and cmml
-
3:32
glasdegib in combination with azacitidine in mds, aml and cmml
-
2:14
insights into the enhance-3 study: azacitidine plus venetoclax with or without magrolimab in aml